- Report
- August 2025
- 188 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- February 2025
- 199 Pages
Global
From €3969EUR$4,500USD£3,487GBP
- Report
- September 2025
- 250 Pages
Global
From €3961EUR$4,490USD£3,479GBP
- Report
- March 2024
- 239 Pages
Global
From €5125EUR$6,013USD£4,350GBP
- Report
- July 2024
- 150 Pages
Global
From €5248EUR$5,950USD£4,611GBP
- Report
- May 2023
- 163 Pages
Global
From €5248EUR$5,950USD£4,611GBP
- Report
- October 2024
- 200 Pages
Global
From €3308EUR$3,750USD£2,906GBP
- Report
- January 2021
- 201 Pages
Global
From €3175EUR$3,600USD£2,790GBP
- Report
- September 2025
- 87 Pages
Global
From €3500EUR$4,251USD£3,182GBP
- Report
- August 2025
- 105 Pages
Global
From €3500EUR$4,251USD£3,182GBP
- Report
- September 2023
- 74 Pages
Global
From €3500EUR$4,251USD£3,182GBP
Menactra is a vaccine used to protect against meningococcal disease, a serious bacterial infection that can cause meningitis and other life-threatening illnesses. It is approved for use in people aged 9 months to 55 years old. The vaccine is administered as a single dose and is available in both pediatric and adult formulations.
Menactra is a part of the larger vaccine market, which includes a variety of products designed to protect against a range of infectious diseases. Vaccines are an important tool in public health, helping to reduce the spread of disease and protect vulnerable populations.
The Menactra market is highly competitive, with a number of companies offering similar products. These include Sanofi Pasteur, GlaxoSmithKline, Merck, Pfizer, and Novartis. Show Less Read more
